Reporter brief
Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain: a Randomized, Double-blind, Placebo-controlled Trial
What happened
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- This is a protocol or background document, not a results report—no outcome data are presented.
- The efficacy or safety of semaglutide in this specific population and timing cannot be assessed from this abstract.
- Whether combining semaglutide with conversion surgery outperforms either intervention alone is not addressed in the material provided.
Study design and sample
Rct; Human.
Patients with recurrent weight gain after sleeve gastrectomy (SG)
- Design
- Rct
- Sample
- —
- Journal
- General Committee of Teaching Hospitals and Institutes, Egypt
- Published
- Oct 5, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the GLP-1 agonists timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.